Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

OP 101

Next Previous
Drug Profile

OP 101

Alternative Names: Dendrimer N-acetyl-cysteine; OP-101

Latest Information Update: 28 Jul 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ashvattha Therapeutics
  • Developer Orpheris
  • Class Amines; Anti-inflammatories; Antiparkinsonians; Neuroprotectants
  • Mechanism of Action I-kappa B kinase inhibitors; Janus kinase inhibitors; MAP kinase kinase kinase inhibitors; NF-kappa B kinase inhibitors; Nuclear importation inhibitors; Oxygen radical scavengers; STAT transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Adrenoleucodystrophy
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II COVID 2019 infections
  • No development reported Adrenoleucodystrophy; Neurological disorders; Parkinson's disease

Most Recent Events

  • 28 Jul 2023 No recent reports of development identified for preclinical development in Parkinson's-disease in USA (IV)
  • 28 Apr 2023 No recent reports of development identified for phase-I development in Adrenoleucodystrophy(In volunteers) in Australia (SC)
  • 12 Aug 2022 Ashvattha Therapeutics terminates phase II trial in COVID-2019 infections in USA (IV) due to lack of enrollment (NCT04458298)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top